Evidence map›Paper›PMID 29142906›Full record

ArticleInternational journal of chronic diseases2017

Hierarchical Modeling of Patient and Physician Determinants of Blood Pressure Outcomes in Hypertensive Patients with and without Diabetes: Pooled Analysis of Six Observational Valsartan Studies with 15,282 Evaluable Patients.

Noha Ashy, Thanh-Nga Nguyen, Kris Denhaerynck, Mahdi Gharaibeh, Abdulaziz Alhossan, Stefaan Vancayzeele, Heidi Brié, Ann Aerts, Karen MacDonald, Ivo Abraham

Open access · hybridAbstract read
In one paragraph

Article in International journal of chronic diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 80% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 4 countries.

Noha AshyCollege of Pharmacy, King Abdulaziz University, P.O. Box 80200, Jeddah 21589, Saudi Arabia.
Thanh-Nga NguyenCenter for Health Outcomes and PharmacoEconomic Research, University of Arizona, 1295 N Martin, Tucson, AZ 85721, USA.
Kris DenhaerynckMatrix45, 6159 W Sunset Rd, Tucson, AZ, USA.
Mahdi GharaibehCenter for Health Outcomes and PharmacoEconomic Research, University of Arizona, 1295 N Martin, Tucson, AZ 85721, USA.
Abdulaziz AlhossanCenter for Health Outcomes and PharmacoEconomic Research, University of Arizona, 1295 N Martin, Tucson, AZ 85721, USA.ORCID 0000-0001-5849-6756
Stefaan VancayzeeleNovartis Pharma, Medialaan 40, 1800 Vilvoorde, Belgium.
Heidi BriéNovartis Pharma, Medialaan 40, 1800 Vilvoorde, Belgium.ORCID 0000-0003-0730-9580
Ann AertsNovartis Foundation, Novartis Campus, Forum 1-3.97, 4002 Basel, Switzerland.
Karen MacDonaldMatrix45, 6159 W Sunset Rd, Tucson, AZ, USA.ORCID 0000-0002-4568-9783
Ivo AbrahamCenter for Health Outcomes and PharmacoEconomic Research, University of Arizona, 1295 N Martin, Tucson, AZ 85721, USA.ORCID 0000-0003-0490-4421
University of Arizona · USNovartis (Belgium) · BEMatrix Research (United States) · USNovartis Foundation · CHUniversity of Basel · CHUniversity of Wyoming · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We pooled data from 6 valsartan-related studies including 3,658 diabetic and 11,624 nondiabetic patients to evaluate blood pressure (BP) outcomes after approximately 90 days of second- or later-line valsartan treatment. Hierarchical linear and logistic regressions were applied to identify determinants of BP outcomes. Similar reductions in BP values and similar BP control rates were achieved in both groups after approximately 90 days of therapy. The modeling analyses identified several common and different patient- and physician-related determinants of BP outcomes for both groups, many of which are modifiable or clinically manageable. Through varying in terms of association and influence between the diabetic and nondiabetic groups, patient-related determinants included age, BP at diagnosis of hypertension, risk factors, valsartan regimen, concomitant antihypertensive treatment, and adherence; and physician-related determinants included gender, years in practice, and hypertension management. In summary, in both diabetic and nondiabetic patients, the use of valsartan-centric treatment regimens in second- or later-line antihypertensive treatment is associated with significant reductions in BP level and improvement in BP control. The determinants identified in modeling provide guidance to clinicians in the common and differential management of hypertension in diabetic and nondiabetic patients.

Identifiers

PMID29142906
PMCPMC5632928
OpenAlexW2757312088

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.